Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Canopy Growth CorporationNASDAQ: CGC

Capital Expenditures · Q4 FY2025 · quarter ended Mar 2026

Capital expenditures declines year over year

Q4 FY2025 capital expenditures of CA$1.11M (cash outflow) fell 64.8% year over year, behind the -41.0% change in trailing-twelve-month capital expenditures. Sequentially, it fell 57.3% from the prior quarter. Over 3 fiscal years it compounded at -10.7% a year.

Context

  • Capital expenditures amounted to 1.5% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -64.8% toward the trailing-twelve-month pace of -41.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$1.11M-57.3% QoQ
Last fiscal yearMar 2026
-CA$7.44M-34.1% YoY
LTMMar 2026
-CA$6.66M-41.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.8%——
1 year-34.1%——
3-year CAGR-10.7%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

CAD · from the cash flow

Latest · FY2025
(7.44M) CAD
Year-over-year change
+34.1%

Capital Expenditures vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -41.0% is the 4th highest of 9, against a peer median of -69.7%.
  • Capital expenditures amounts to 2.1% of revenue for CGC, versus a peer median of 2.9%.
CGC Competitors
Capital Expenditures for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$22.56M CAD+19.6%+23.0%7.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$6.91M USD—-23.5%5.1%
CGCCanopy Growth CorporationLTM Mar 2026CA$6.66M CAD-41.0%-10.7%2.1%
DHDefinitive Healthcare Corp.LTM Mar 2026$2.22M USD-88.8%+26.2%0.9%
TKNOAlpha Teknova, Inc.LTM Mar 2026$1.16M USD-4.6%-65.6%2.8%
LYELLyell Immunopharma, Inc.LTM Mar 2026$623K USD-8.4%-68.2%2009.7%
CABACabaletta Bio, Inc.LTM Mar 2026$444K USD-79.7%-20.6%—
BIOABioAge Labs, Inc.LTM Mar 2026$319K USD-59.7%+91.1%3.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81K USD-99.8%-43.2%1.0%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$3K USD-97.1%-37.0%0.0%
Peer median (excluding CGC) —-69.7%-23.5%2.9%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.